BARR PHARMACEUTICALS INC

BARR PHARMACEUTICALS INC operates as a specialty phase of the Pharmaceutical Preparations SIC universe, developing therapeutic generics and branded formulations that span acute care, central nervous system, and specialty clinic needs; its core services combine formulation licensing, contract manufacturing, and regulatory support to help hospitals, physician groups, and specialty pharmacies source compliant molecules at scale. The company’s R&D teams are tasked with refining delivery systems and bioequivalence dossiers while sales and supply-chain partners stay attuned to the cadence of formularies and insurer contracts, so target customers appreciate predictable availability and full pharmacovigilance documentation. Because the firm still navigates tightening FDA enforcement, federal reimbursement shifts, and the perpetual risk of recalls or inspection observations, compliance and quality systems are integral to every launch and partnership negotiation. CIK 10081 anchors its SEC relationship, though its latest filing is not readily available; investors should watch for new disclosures in this highly regulated arena, and view live SEC filings on Earnings Feed for updates.

Source: Earnings Feed research · last updated 11/24/2025